| In silico simulation of a clinical trial with anti-CTLA-4 and anti-PD-L1 immunotherapies in metastatic breast cancer using a systems pharmacology model H Wang, O Milberg, IH Bartelink, P Vicini, B Wang, R Narwal, L Roskos, ... Royal Society Open Science 6 (5), 2019 | 52 | 2019 |
| Conducting a virtual clinical trial in HER2-negative breast cancer using a quantitative systems pharmacology model with an epigenetic modulator and immune checkpoint inhibitors H Wang, RJ Sové, M Jafarnejad, S Rahmeh, EM Jaffee, V Stearns, ... Frontiers in Bioengineering and Biotechnology 8, 141, 2020 | 28 | 2020 |
| Combination therapy with T cell engager and PD-L1 blockade enhances the antitumor potency of T cells as predicted by a QSP model H Ma, H Wang, RJ Sové, J Wang, C Giragossian, AS Popel Journal for immunotherapy of cancer 8 (2), 2020 | 28 | 2020 |
| QSP‐IO: a quantitative systems pharmacology toolbox for mechanistic multiscale modeling for Immuno‐oncology applications RJ Sové, M Jafarnejad, C Zhao, H Wang, H Ma, AS Popel CPT: pharmacometrics & systems pharmacology 9 (9), 484-497, 2020 | 22 | 2020 |
| Quantitative systems pharmacology model predictions for efficacy of atezolizumab and nab-paclitaxel in triple-negative breast cancer H Wang, H Ma, RJ Sové, LA Emens, AS Popel Journal for immunotherapy of cancer 9 (2), 2021 | 20 | 2021 |
| A quantitative systems pharmacology model of T cell engager applied to solid tumor H Ma, H Wang, RJ Sove, M Jafarnejad, CH Tsai, J Wang, C Giragossian, ... The AAPS Journal 22, 1-16, 2020 | 18 | 2020 |
| Integrating single cell sequencing with a spatial quantitative systems pharmacology model spQSP for personalized prediction of triple-negative breast cancer immunotherapy response S Zhang, C Gong, A Ruiz-Martinez, H Wang, E Davis-Marcisak, ... Immunoinformatics 1, 100002, 2021 | 16 | 2021 |
| Virtual clinical trials of anti-PD-1 and anti-CTLA-4 immunotherapy in advanced hepatocellular carcinoma using a quantitative systems pharmacology model RJ Sové, BK Verma, H Wang, WJ Ho, M Yarchoan, AS Popel Journal for immunotherapy of cancer 10 (11), e005414, 2022 | 9 | 2022 |
| Simulations of tumor growth and response to immunotherapy by coupling a spatial agent-based model with a whole-patient quantitative systems pharmacology model A Ruiz-Martinez, C Gong, H Wang, RJ Sové, H Mi, H Kimko, AS Popel PLoS computational biology 18 (7), e1010254, 2022 | 8 | 2022 |
| Systems biology of angiogenesis signaling: Computational models and omics Y Zhang, H Wang, RHM Oliveira, C Zhao, AS Popel WIREs mechanisms of disease 14 (4), e1550, 2022 | 7 | 2022 |
| Dynamics of tumor-associated macrophages in a quantitative systems pharmacology model of immunotherapy in triple-negative breast cancer H Wang, C Zhao, CA Santa-Maria, LA Emens, AS Popel iScience 25 (8), 104702, 2022 | 3 | 2022 |
| Generating immunogenomic data-guided virtual patients using a QSP model to predict response of advanced NSCLC to PD-L1 inhibition H Wang, T Arulraj, H Kimko, AS Popel bioRxiv, 2023.04.25.538191, 2023 | | 2023 |
| Predicting response to PD-L1 inhibition in NSCLC using a quantitative systems pharmacology model guided by immunogenomic data H Wang, T Arulraj, AS Popel Cancer Research 83 (7_Supplement), 5697, 2023 | | 2023 |
| (M1530-02-11) Single Cell Sequencing Combined with a Novel Spatial Quantitative Systems Pharmacology Model spQSP Predict Response of Triple-Negative Breast Cancer to Immunotherapy S Zhang, C Gong, A Ruiz-Martinez, H Wang, A Deshpande, E Marcisak, ... AAPS 2021 PHARMSCI 360, 2021 | | 2021 |
| IN SILICO VIRTUAL CLINICAL TRIALS OF ATEZOLIZUMAB AND NAB-PACLITAXEL IN ADVANCED TRIPLE-NEGATIVE BREAST CANCER. H Wang, H Ma, R Sove, L Emens, A Popel CLINICAL PHARMACOLOGY & THERAPEUTICS 109, S23-S23, 2021 | | 2021 |
| Simulations of Combination Therapy in Hepatocellular Carcinoma Using a Quantitative Systems Pharmacology Model RJ Sove, M Jafarnejad, H Wang, M Yarchoan, AS Popel The FASEB Journal 34 (S1), 1-1, 2020 | | 2020 |
Aleksander S. PopelProfessor of Biomedical Engineering, Johns Hopkins University, School of Medicine在 jhu.edu 的电子邮件经过验证
